A new potential biomarker raises concerns over the current standard for treating COVID-19 induced blood clots with high dose blood thinners.
Targeting this inside-the-cell checkpoint could potentially improve response to cancer immunotherapy.
Engineers and oncologists teamed to develop a microfluidic chip capable of capturing the body’s natural killer immune cells to harvest their cancer-killing exosomes.
New SARS-CoV-2 mutations in the U.K. and the U.S. have raised alarms. A Michigan expert weighs in.
Approach could improve predictive value of genetic screening.